>
-Announcement for the purposes of Rule 2.8 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”)-BLUETTI Opens First Flagship Store in Munich, Germany for Hands-on Experience-10 Trucos para ahorrar en la factura de la luz en España-Leading Solo VC Ozi Amanat Collects $300 Million-Jack Nathan Health Provides Corporate Update-CORRECTING and REPLACING – Canadian Spirit Resources Inc. Announces Third Quarter 2022 Financial Results-Friedman Industries, Incorporated Announces Second Quarter Results and Provides Near-term Outlook-Wesco Declares Quarterly Dividend on Preferred Stock-InterDigital Declares Regular Quarterly Cash Dividend-BeeHero Raises $42 Million Series B to Accelerate Deployment of Its Data-driven Precision Pollination Platform-Athene Holding Ltd. Declares Fourth Quarter 2022 Preferred Stock Dividends-Horace Mann declares quarterly dividend-PotlatchDeltic Board Declares $0.95 Special Dividend and Increases Regular Distribution 2.3%-FCPT Announces Acquisition of a Cheesecake Factory Property and a Dual-tenant Starbucks and AT&T Property for $12.3 Million-EVERTEC Announces Refinancing of Credit Facilities-Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)-Brookfield Office Properties Announces Reset Dividend Rate and Conversion Privileges on Its Class AAA Series II Preference Shares-CORRECTING and REPLACING Essential Utilities’ Aqua Illinois Subsidiary Acquires Oak Brook Water Assets-Correction: KOREA FAIR TRADE COMMISSION (KFTC) – APPEAL PROCEEDINGS UPDATE-KOREA FAIR TRADE COMMISSION (KFTC) – POINT SUR LA PROCEDURE D’APPEL

Global Liver Fibrosis Treatment Market to Surpass US$ 33.4 Billion by 2030, Says Coherent Market Insights (CMI)

| Source: CMI


Seattle, Aug. 08, 2022 (GLOBE NEWSWIRE) — According to Coherent Market Insights, the global liver fibrosis treatment market is estimated to be valued at US$ 14.7 billion in 2022 and is expected to exhibit a CAGR of 10.8% during the forecast period (2022-2030).

Key Trends and Analysis of the Global Liver Fibrosis Treatment Market:

Increasing incidence of liver fibrosis, along with growing prevalence of risk factors such as chronic infection with hepatitis B or C virus, compromised immune system due to co-infection with human immunodeficiency virus (HIV) or use of immunosuppressive drugs after a liver transplant are expected to fuel growth of the liver fibrosis treatment market. For instance, in June 2022, according to data published by World Health Organization, it was estimated that 296 million people were living with chronic hepatitis B infection in 2019, with 1.5 million new infections every year. In 2019, hepatitis B resulted in an estimated 820 000 deaths, mostly from cirrhosis and hepatocellular carcinoma (primary liver cancer). Hepatitis C prevalence was 0.49% among general population in the U.S. region in 2019. The incidence of hepatitis C in the region was 230 000, while the deaths were estimated to be 77000 in 2019.

Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2320

Key Market Takeaways:

Global liver fibrosis treatment market is expected to exhibit a CAGR of 10.8% during the forecast period due to increasing research and development activities for developing Non-Contrast Magnetic Resonance Imaging methods for detecting, discriminating, and measuring liver fibrosis. For instance, in May 2018, Children’s Hospital Medical Center, academic pediatric acute care children’s hospital, was working on developing Non-Contrast Magnetic Resonance Imaging methods for detecting, discriminating, and measuring liver fibrosis. The development of the Non-Contrast Magnetic Resonance Imaging methods will make easy to detect the liver fibrosis type and any infection related to liver which would help physicians to treat it with correct medication. Thus, the launch of the non-contrast magnetic resonance Imaging methods would help in easy diagnosis of liver fibrosis.

Among treatment type, hepatotropic drug accounted for significant market share in liver fibrosis treatment market, as it enables safe and efficient treatment for reducing fibrosis in patients.

Among region, North America market accounted for the largest market share, followed by Europe in 2022. This is owing to increasing burden of potential risk factors leading to liver fibrosis such as obesity, type 2 diabetic, metabolic fibrosis, hepatitis C, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), among others. For instance, according to the NASH Education Program, 2018 data findings, NAFLD is most common chronic liver condition in Western population of economies in the Europe and the U.S. region as compared to obesity and type 2 diabetes epidemics. Furthermore, in the U.S., hepatitis C is the most common chronic viral infection found in blood and spread through contact with blood. According to the data published by the Center for Disease Control and Prevention, researchers estimate that about 2.7 million to 3.9 million people in the U.S. had chronic hepatitis C in the year 2018.

Competitive Landscape:

Key players operating in the global liver fibrosis treatment market include Gilead Sciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb, Johnson and Johnson, Novartis AG, Vertex Pharmaceuticals Incorporated, Pfizer Inc., FibroGen, Inc., and Pharmaxis Limited

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2320

Market Segmentation:

  • Global Liver Fibrosis Treatment , By Treatment Type :
    • Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
    • ACE Inhibitors
    • Hepatotropic Drug
    • Others
  • Global Liver Fibrosis Treatment , By Condition:
    • Chronic Liver Diseases
    • Hepatitis C
    • Nonalcoholic Steatohepatitis
  • Global Liver Fibrosis Treatment , By Distribution Channel:
    • Hospitals
    • Specialty Clinics
    • Others
  • Global Liver Fibrosis Treatment , By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa

Related Market Intelligence Reports:

Nonalcoholic Steatohepatitis Treatment Market, by Drug (Cenicriviroc, Elafibranor, Ocaliva, and Selonsertib), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030

Gastroparesis Treatment Market, By Drug (Metoclopramide, Erythromycin, Domperidone, Others), By Type (Diabetic gastroparesis, Idiopathic gastroparesis, Post-surgical gastroparesis), By Route of Administration (Intravenous, Nasal, Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, Africa) – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Follow Us: LinkedInTwitter



Contact Data

              Mr. Shah Senior Client Partner – Business Development Coherent Market Insights  Phone: US: +1-206-701-6702 UK: +44-020-8133-4027 Japan: +81-050-5539-1737 India: +91-848-285-0837 Email: sales@coherentmarketinsights.com Website: https://www.coherentmarketinsights.com              

Leave a Comment